INTERVIEW: Genexine Aiming To Become Global Player
This article was originally published in PharmAsia News
Executive Summary
Genexine is set to progress and expand this year the clinical development of its leading assets, orphan disease drugs and cancer immunotherapies. The South Korean biotech company's CEO talks in an interview with PharmAsia News about its R&D and business strategies, as well as the challenges faced by the wider Korean biotech industry.
You may also be interested in...
Genexine Advances DNA Vaccine With Mid-Stage Cervical Cancer Success
The Korean firm’s DNA vaccine has shown promise in a Phase II cervical cancer trial in combination with Merck’s Keytruda, prompting the firm to tout potential in the difficult PD-1 negative group.
Genexine Hopes To Become 'Asia’s Amgen' After ToolGen Merger
With an ambition to become an Amgen-like global biopharma, South Korea's Genexine decides to merge with local genome editing firm ToolGen to progress potential global blockbusters such as universal CAR-T therapies.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.